Menu
Topic:
Ebola vaccine
Sponsor:
INSERM, NIH, LSHTM
Funder:
National Institute of Health (NIH), INSERM, London School of Hygiène and Tropical Medecine (LSHTM), European Commission (EDCTP2)
The PREVAC trial is a phase 2b randomized control trial evaluating the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults from 4 west-african countries (Guinea, Mali, Sierra-Leone, Liberia). Participants are randomized to receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA) boost, or the rVSVΔG-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo. The follow-up of the participant is currently ongoing within the PREVAC-UP projet funded by EDCTP2.